Chemotherapy
Novel approach may eliminate survival disparity in HSCT, greatly expand access
Use of post-transplant cyclophosphamide prophylaxis to prevent graft-versus-host disease could greatly expand access to hematopoietic stem cell transplantation, according to results of a retrospective study.
Mouthwash test could detect risk for recurrence of head and neck cancer
A mouthwash-based biomarker test has demonstrated efficacy for detecting risk of head and neck cancer recurrence, according to results of a nonrandomized clinical trial.
Pembrolizumab regimen extends OS in triple-negative breast cancer
Use of pembrolizumab with neoadjuvant chemotherapy and as monotherapy in the adjuvant setting extended OS for patients with early-stage triple-negative breast cancer, according to results from the randomized phase 3 KEYNOTE-522 trial.
Durvalumab regimen improves outcomes in muscle-invasive bladder cancer
Use of durvalumab before and after radical cystectomy improved outcomes for patients with muscle-invasive bladder cancer, according to results of the randomized phase 3 NIAGARA trial.
Benefit of adjuvant pembrolizumab in endometrial cancer varies by mismatch repair status
The addition of pembrolizumab to adjuvant chemotherapy improved DFS for certain women with newly diagnosed high-risk endometrial cancer, according to randomized phase 3 study results presented at ESMO Congress.
Axi-cel ‘can be curative’ for large B-cell lymphoma, but nonrelapse mortality a concern
A real-world evaluation of axicabtagene ciloleucel for individuals with relapsed or refractory large B-cell lymphoma showed 5-year OS, PFS and disease-specific survival rates comparable to those observed in clinical trials.
Risk for second primary malignancies no greater with CAR-T than other standard therapies
Patients who received chimeric antigen receptor T-cell therapy did not exhibit increased risk for second primary malignancies compared with those who received other standard treatments, according to a systematic review and meta-analysis.
Regimen ‘one of the best options’ for locally advanced rectal cancer
Modified FOLFIRINOX induction chemotherapy prior to standard chemoradiation, surgery and adjuvant chemotherapy improved outcomes for patients with locally advanced rectal cancer, according to a long-term analysis of a randomized phase 3 trial.
Inflation Reduction Act saves patients with cancer thousands in out-of-pocket spending
The Inflation Reduction Act’s cap on out-of-pocket spending saved patients with cancer more than $7,000 a year on oral chemotherapy medications, a research letter analysis published in JAMA Network Open showed.
Perioperative nivolumab improves outcomes in resectable NSCLC
Immunotherapy before and after surgery significantly improved EFS compared with neoadjuvant immunotherapy only for patients with resectable non-small cell lung cancer, according to a comparison of results from two randomized phase 3 trials.